Financhill
Sell
24

MOLN Quote, Financials, Valuation and Earnings

Last price:
$4.24
Seasonality move :
-25.38%
Day range:
$4.33 - $4.35
52-week range:
$3.32 - $12.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
21.67x
P/B ratio:
1.02x
Volume:
581
Avg. volume:
2.5K
1-year change:
12.03%
Market cap:
$159.7M
Revenue:
$5.6M
EPS (TTM):
-$1.81

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MOLN
Molecular Partners AG
-- -$0.43 -100% -8.38% $10.78
ACIU
AC Immune SA
-- -$0.21 -95.08% -273.39% $10.07
ADXN
Addex Therapeutics
$236.3K -- 2.35% -- $30.00
CRSP
CRISPR Therapeutics AG
$9.1M -$1.28 -96.36% -11.56% $83.60
NLSP
NLS Pharmaceutics
-- -- -- -- --
NVS
Novartis AG
$13.6B $2.24 6.82% 57% $108.96
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MOLN
Molecular Partners AG
$4.33 $10.78 $159.7M -- $0.00 0% 21.67x
ACIU
AC Immune SA
$2.29 $10.07 $226.6M -- $0.00 0% --
ADXN
Addex Therapeutics
$7.54 $30.00 $8.1M -- $0.00 0% 13.93x
CRSP
CRISPR Therapeutics AG
$42.12 $83.60 $3.6B -- $0.00 0% --
NLSP
NLS Pharmaceutics
$1.58 -- $6M -- $0.00 0% --
NVS
Novartis AG
$109.06 $108.96 $215.4B 18.55x $3.87 3.55% 4.29x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MOLN
Molecular Partners AG
-- 3.153 -- 14.08x
ACIU
AC Immune SA
-- 5.657 -- 1.66x
ADXN
Addex Therapeutics
-- 3.522 -- 4.36x
CRSP
CRISPR Therapeutics AG
-- 2.038 -- 21.97x
NLSP
NLS Pharmaceutics
-- 3.791 -- --
NVS
Novartis AG
40.07% 0.604 15.32% 0.80x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MOLN
Molecular Partners AG
-- -$16.8M -37.36% -37.36% -2407.93% -$14.2M
ACIU
AC Immune SA
-- -$21.2M -37.26% -37.26% -1386.46% $5.4M
ADXN
Addex Therapeutics
-- -$719.5K 91.08% 91.08% -2836.3% -$713.3K
CRSP
CRISPR Therapeutics AG
$35M -$64.6M -18.65% -18.65% -184.54% -$50.3M
NLSP
NLS Pharmaceutics
-- -- -- -- -- --
NVS
Novartis AG
$10.2B $3.5B 16.91% 27.64% 26.26% $3.1B

Molecular Partners AG vs. Competitors

  • Which has Higher Returns MOLN or ACIU?

    AC Immune SA has a net margin of -2408.81% compared to Molecular Partners AG's net margin of -1389.36%. Molecular Partners AG's return on equity of -37.36% beat AC Immune SA's return on equity of -37.26%.

    Company Gross Margin Earnings Per Share Invested Capital
    MOLN
    Molecular Partners AG
    -- -$0.34 $165M
    ACIU
    AC Immune SA
    -- -$0.18 $124.3M
  • What do Analysts Say About MOLN or ACIU?

    Molecular Partners AG has a consensus price target of $10.78, signalling upside risk potential of 148.97%. On the other hand AC Immune SA has an analysts' consensus of $10.07 which suggests that it could grow by 339.68%. Given that AC Immune SA has higher upside potential than Molecular Partners AG, analysts believe AC Immune SA is more attractive than Molecular Partners AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    MOLN
    Molecular Partners AG
    3 1 0
    ACIU
    AC Immune SA
    3 0 0
  • Is MOLN or ACIU More Risky?

    Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.226, suggesting its more volatile than the S&P 500 by 22.632%.

  • Which is a Better Dividend Stock MOLN or ACIU?

    Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MOLN or ACIU?

    Molecular Partners AG quarterly revenues are $787.5K, which are smaller than AC Immune SA quarterly revenues of $1.3M. Molecular Partners AG's net income of -$12.8M is higher than AC Immune SA's net income of -$18M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 21.67x versus -- for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MOLN
    Molecular Partners AG
    21.67x -- $787.5K -$12.8M
    ACIU
    AC Immune SA
    -- -- $1.3M -$18M
  • Which has Higher Returns MOLN or ADXN?

    Addex Therapeutics has a net margin of -2408.81% compared to Molecular Partners AG's net margin of -2841.85%. Molecular Partners AG's return on equity of -37.36% beat Addex Therapeutics's return on equity of 91.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    MOLN
    Molecular Partners AG
    -- -$0.34 $165M
    ADXN
    Addex Therapeutics
    -- -$2.78 $13.1M
  • What do Analysts Say About MOLN or ADXN?

    Molecular Partners AG has a consensus price target of $10.78, signalling upside risk potential of 148.97%. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 297.88%. Given that Addex Therapeutics has higher upside potential than Molecular Partners AG, analysts believe Addex Therapeutics is more attractive than Molecular Partners AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    MOLN
    Molecular Partners AG
    3 1 0
    ADXN
    Addex Therapeutics
    0 0 0
  • Is MOLN or ADXN More Risky?

    Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 1.757, suggesting its more volatile than the S&P 500 by 75.723%.

  • Which is a Better Dividend Stock MOLN or ADXN?

    Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MOLN or ADXN?

    Molecular Partners AG quarterly revenues are $787.5K, which are larger than Addex Therapeutics quarterly revenues of $62.3K. Molecular Partners AG's net income of -$12.8M is lower than Addex Therapeutics's net income of -$1.8M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 21.67x versus 13.93x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MOLN
    Molecular Partners AG
    21.67x -- $787.5K -$12.8M
    ADXN
    Addex Therapeutics
    13.93x -- $62.3K -$1.8M
  • Which has Higher Returns MOLN or CRSP?

    CRISPR Therapeutics AG has a net margin of -2408.81% compared to Molecular Partners AG's net margin of -106.6%. Molecular Partners AG's return on equity of -37.36% beat CRISPR Therapeutics AG's return on equity of -18.65%.

    Company Gross Margin Earnings Per Share Invested Capital
    MOLN
    Molecular Partners AG
    -- -$0.34 $165M
    CRSP
    CRISPR Therapeutics AG
    -- -$0.44 $1.9B
  • What do Analysts Say About MOLN or CRSP?

    Molecular Partners AG has a consensus price target of $10.78, signalling upside risk potential of 148.97%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $83.60 which suggests that it could grow by 98.48%. Given that Molecular Partners AG has higher upside potential than CRISPR Therapeutics AG, analysts believe Molecular Partners AG is more attractive than CRISPR Therapeutics AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    MOLN
    Molecular Partners AG
    3 1 0
    CRSP
    CRISPR Therapeutics AG
    12 11 1
  • Is MOLN or CRSP More Risky?

    Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.767, suggesting its more volatile than the S&P 500 by 76.677%.

  • Which is a Better Dividend Stock MOLN or CRSP?

    Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MOLN or CRSP?

    Molecular Partners AG quarterly revenues are $787.5K, which are smaller than CRISPR Therapeutics AG quarterly revenues of $35M. Molecular Partners AG's net income of -$12.8M is higher than CRISPR Therapeutics AG's net income of -$37.3M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 21.67x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MOLN
    Molecular Partners AG
    21.67x -- $787.5K -$12.8M
    CRSP
    CRISPR Therapeutics AG
    -- -- $35M -$37.3M
  • Which has Higher Returns MOLN or NLSP?

    NLS Pharmaceutics has a net margin of -2408.81% compared to Molecular Partners AG's net margin of --. Molecular Partners AG's return on equity of -37.36% beat NLS Pharmaceutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MOLN
    Molecular Partners AG
    -- -$0.34 $165M
    NLSP
    NLS Pharmaceutics
    -- -- --
  • What do Analysts Say About MOLN or NLSP?

    Molecular Partners AG has a consensus price target of $10.78, signalling upside risk potential of 148.97%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 15089.87%. Given that NLS Pharmaceutics has higher upside potential than Molecular Partners AG, analysts believe NLS Pharmaceutics is more attractive than Molecular Partners AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    MOLN
    Molecular Partners AG
    3 1 0
    NLSP
    NLS Pharmaceutics
    0 0 0
  • Is MOLN or NLSP More Risky?

    Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock MOLN or NLSP?

    Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MOLN or NLSP?

    Molecular Partners AG quarterly revenues are $787.5K, which are larger than NLS Pharmaceutics quarterly revenues of --. Molecular Partners AG's net income of -$12.8M is higher than NLS Pharmaceutics's net income of --. Notably, Molecular Partners AG's price-to-earnings ratio is -- while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 21.67x versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MOLN
    Molecular Partners AG
    21.67x -- $787.5K -$12.8M
    NLSP
    NLS Pharmaceutics
    -- -- -- --
  • Which has Higher Returns MOLN or NVS?

    Novartis AG has a net margin of -2408.81% compared to Molecular Partners AG's net margin of 20.79%. Molecular Partners AG's return on equity of -37.36% beat Novartis AG's return on equity of 27.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    MOLN
    Molecular Partners AG
    -- -$0.34 $165M
    NVS
    Novartis AG
    75.48% $1.41 $73.6B
  • What do Analysts Say About MOLN or NVS?

    Molecular Partners AG has a consensus price target of $10.78, signalling upside risk potential of 148.97%. On the other hand Novartis AG has an analysts' consensus of $108.96 which suggests that it could fall by -0.09%. Given that Molecular Partners AG has higher upside potential than Novartis AG, analysts believe Molecular Partners AG is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    MOLN
    Molecular Partners AG
    3 1 0
    NVS
    Novartis AG
    0 9 2
  • Is MOLN or NVS More Risky?

    Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.540, suggesting its less volatile than the S&P 500 by 45.99%.

  • Which is a Better Dividend Stock MOLN or NVS?

    Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 3.55% to investors and pays a quarterly dividend of $3.87 per share. Molecular Partners AG pays -- of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios MOLN or NVS?

    Molecular Partners AG quarterly revenues are $787.5K, which are smaller than Novartis AG quarterly revenues of $13.6B. Molecular Partners AG's net income of -$12.8M is lower than Novartis AG's net income of $2.8B. Notably, Molecular Partners AG's price-to-earnings ratio is -- while Novartis AG's PE ratio is 18.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 21.67x versus 4.29x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MOLN
    Molecular Partners AG
    21.67x -- $787.5K -$12.8M
    NVS
    Novartis AG
    4.29x 18.55x $13.6B $2.8B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Goldman Sachs Stock a Buy Sell or Hold?
Is Goldman Sachs Stock a Buy Sell or Hold?

When the Federal Reserve started hiking rates in 2022, banks’…

Is Reddit a Buy on the Dip?
Is Reddit a Buy on the Dip?

Reddit (NYSE:RDDT) share price has been on the proverbial ropes…

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock